【2h】

Femoro-popliteal endovascular interventions

机译:股腘血管内介入治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Peripheral artery disease (PAD) is a worldwide major health challenge, and it is a strong predictor of mortality and morbidity. The advances in PAD treatment have resulted in many therapeutic options or endovascular interventions (EVIs) for endovascular revascularization if drug therapy does not lead to substantial improvement. Randomized controlled trials (RCTs) have reported the efficacy of various EVIs such as atherectomy, stents, and medicated balloons over the traditional transluminal angioplasty; however, the standard treatment for PAD remains unclear due to the lack of head-to-head comparative studies between different EVIs. Additionally, the variable outcomes between clinical trials regarding the functional capacity and quality of life (QoL) make it difficult to ascertain the superiority of one particular EVI over another. Therefore, the latest PAD clinical trials should include head-to-head comparisons between different EVIs, and this review aimed to highlight the femoro-popliteal EVIs, evidence supporting each intervention and why those EVIs are used.
机译:外周动脉疾病 (PAD) 是一项世界性的重大健康挑战,它是死亡率和发病率的有力预测指标。如果药物治疗没有导致实质性改善,PAD 治疗的进步导致了许多用于治疗血管内血运重建的治疗选择或血管内干预 (EVOI)。随机对照试验 (RCT) 报道了各种 EVI(如斑块切除术、支架和药物球囊)优于传统腔内血管成形术的疗效;然而,由于缺乏不同 EVI 之间的头对头比较研究,PAD 的标准治疗仍不清楚。此外,临床试验之间关于功能能力和生活质量 (QoL) 的不同结果使得很难确定一种特定 EVI 优于另一种。因此,最新的 PAD 临床试验应包括不同 EVI 之间的头对头比较,本综述旨在强调股腘 EVIs、支持每种干预措施的证据以及使用这些 EVI 的原因。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号